|Scientific Subdivisions | The Journal of Molecular Diagnostics | Contact AMP | Sign In | Join / Renew | Go To CHAMP 2.0|
AMP 2013 Annual Meeting
November 14-16, 2013
Phoenix Convention Center
Corporate Workshop Day
November 13, 2013
Visit Meeting Page
AMP 2013 MGP Review Course
April 4-7, 2013
Double Tree by Hilton Hotel
Bethesda - Washington DC
Visit Course Page
May 10, 2013: Today a coalition representing over 120,000 medical and laboratory professionals and institutions that perform the vast majority of clinical molecular pathology testing in the United States released a joint statement regarding new Medicare prices for those tests.
Take advantage of this opportunity to share your work at the AMP 2013 Annual Meeting, November 14-16 in Phoenix. Accepted abstracts will be published in the November 2013 issue of The Journal of Molecular Diagnostics. More Information...
The guideline was developed to establish standards for testing for EGFR and ALK, helping to guide targeted therapies. Pathologists are encouraged to implement the new guideline at their institutions and into their practices to help improve the effectiveness of lung cancer treatment. More information...
View the webcast (wmv file)
April 2013: The AMP Professional Relations Committee commented on the AHRQ draft report, "Update on Genetic Tests Currently Available for Clinical Use in Common Cancers," identifying methodologic flaws in the data gathering process that have led to gaps in the report's findings.
AMP reaffirms its initial comments stating the Act will address this misalignment between the regulations and pathology practice, and AMP wholeheartedly endorses this legislation.
The emergence of molecular diagnostic testing in lung cancer offers new hope for patients battling the number one cancer killer in the United States and abroad. Now, for the first time after a decade of biomarker testing in lung cancer, a uniform approach for testing for the EGFR mutation and ALK rearrangement along with the availability of targeted therapies offer lung cancer patients the chance for improved quality of life and more time with their loved ones. More Information...
View the most recent newsletter for updates on AMP members and leader's progress in advancing AMP via education, advocacy, and more. View the newsletter.
March 2013: In a letter to the FDA, Jennifer L. Hunt, AMP President warned, "When the FDA includes a brand name of a diagnostic kit on a drug label, the medical community often views this as a tacit endorsement of that one company's test."